Literature DB >> 31852050

Multiples of Median Income: A Tool to Call out Drugs that are High Cost and Low Value.

Thomas E Kottke1, Andrew R Zinkel1, Charles J Fazio1.   

Abstract

As currently priced, many medications are harming society because they are high cost and low value, and they divert resources from interventions that could promote the health and well-being of Americans to a much greater extent. We believe that cost-effectiveness, stated as dollars per quality-adjusted life-year, is not meaningful for many Americans. By contrast, a measure indexed to household income would be far more salient. We therefore propose reporting the costs of drugs and medical devices as multiples of median income of US households. Although this simple change will leave many questions unanswered, we believe that it will contribute to ongoing efforts to increase the value of health care by bringing drug costs into perspective.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31852050      PMCID: PMC6907909          DOI: 10.7812/TPP/19.080

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  11 in total

1.  Judgment under Uncertainty: Heuristics and Biases.

Authors:  A Tversky; D Kahneman
Journal:  Science       Date:  1974-09-27       Impact factor: 47.728

2.  When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard.

Authors:  Ezekiel J Emanuel
Journal:  Health Aff (Millwood)       Date:  2019-04       Impact factor: 6.301

3.  The Economic Consequences of Hospital Admissions.

Authors:  Carlos Dobkin; Amy Finkelstein; Raymond Kluender; Matthew J Notowidigdo
Journal:  Am Econ Rev       Date:  2018-02

4.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Paul A Heidenreich; Paul G Barnett; Mark A Creager; Gregg C Fonarow; Raymond J Gibbons; Jonathan L Halperin; Mark A Hlatky; Alice K Jacobs; Daniel B Mark; Frederick A Masoudi; Eric D Peterson; Leslee J Shaw
Journal:  Circulation       Date:  2014-03-27       Impact factor: 29.690

5.  Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.

Authors:  Christopher J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

6.  Economics of Community Health Workers for Chronic Disease: Findings From Community Guide Systematic Reviews.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jeffrey A Reynolds; Ka Zang Xiong; Christopher D Jones; Betsy J Rodriguez; Krista K Proia; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel
Journal:  Am J Prev Med       Date:  2019-03       Impact factor: 5.043

Review 7.  Housing First Impact on Costs and Associated Cost Offsets: A Review of the Literature.

Authors:  Angela Ly; Eric Latimer
Journal:  Can J Psychiatry       Date:  2015-11       Impact factor: 4.356

8.  Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.

Authors:  Alejandro Arrieta; Jonathan C Hong; Rohan Khera; Salim S Virani; Harlan M Krumholz; Khurram Nasir
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

9.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

10.  Cost-effectiveness of supported housing for homeless persons with mental illness.

Authors:  Robert Rosenheck; Wesley Kasprow; Linda Frisman; Wen Liu-Mares
Journal:  Arch Gen Psychiatry       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.